Medinice

Medinice P/TBV

The Price to Tangible Book Value (P/TBV) of Medinice (ICE.WA) as of Nov 4, 2026 is 10.58. In the previous year, Price to Tangible Book Value (P/TBV) was 84.04 — a change of -87.41% (lower).

P/TBV

10.58

YoY

-87.41%

Last updated:

Price to Tangible Book Value (P/TBV) of Medinice is 2025 10.58 . Price to Tangible Book Value (P/TBV) of Medinice was 2024 84.04 . It decreases by -87.41% lower compared to the previous year.

The Medinice P/TBV history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/TBV
Date
P/TBV
Jan 1, 2018
265.67 PLN
Jan 1, 2019
96.99 PLN
Jan 1, 2020
40.72 PLN
Jan 1, 2021
14.20 PLN
Jan 1, 2022
18.11 PLN
Jan 1, 2023
31.37 PLN
Jan 1, 2024
84.04 PLN
Jan 1, 2025
10.58 PLN
The Medinice P/TBV history
YEARP/TBVYoY
10.58-87.41%
84.04+167.91%
31.37+73.25%
18.11+27.54%
14.20-65.13%
40.72-58.02%
96.99-63.49%
265.67+32.99%
199.77-92.89%
2,811.39—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Medinice Stock analysis

What does Medinice do? Medinice SA generates revenue through the commercialization of medical device solutions, primarily focusing on cardiological and cardiosurgical products. The company's portfolio includes CathAIO, Cryoapplicator, Med-IConsole, Minimax, and Pacepress, which are sold globally via licensing agreements. These products target healthcare providers and medical device manufacturers seeking minimally invasive cardiology solutions. The firm collaborates with research centers in Poland and Europe to develop and commercialize inventions from its co-founders and acquired projects, emphasizing safe and minimally invasive medical technologies. Medinice SA's business model revolves around licensing its proprietary technologies to international partners for the production of medical devices. The company leverages its global potential projects to secure worldwide distribution agreements, ensuring revenue streams from multiple markets. By specializing in cardiology and cardio surgery, Medinice SA positions itself as a provider of innovative solutions for healthcare systems seeking advanced, minimally invasive procedures. The firm's revenue is derived from licensing fees and sales of its medical device solutions, with a focus on cardiological and cardiosurgical applications. Its products, such as CathAIO and Cryoapplicator, are designed to meet global demand for safe and minimally invasive treatments. Medinice SA's strategy involves partnering with research centers in Poland and Europe to enhance its portfolio, ensuring continuous innovation and market relevance in the medical device sector. Medinice is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Medinice stock

Price to Tangible Book Value (P/TBV) of Medinice is 10.58 in 2025.

Price to Tangible Book Value (P/TBV) of Medinice changed from 84.04 to 10.58, representing a -87.41% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Price to Tangible Book Value (P/TBV) Medinice since 2006 – with annual values, charts, and detailed analysis.

P/TBV compares the stock price to tangible book value per share, excluding goodwill and intangibles. It provides a conservative asset-based valuation.

To evaluate Price to Tangible Book Value (P/TBV)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Price to Tangible Book Value (P/TBV).

A 'good' varies by industry and company stage. On Eulerpool, you can compare Price to Tangible Book Value (P/TBV)'s Medinice with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Medinice

All Key Metrics — Medinice